Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia
NCT05018936Phase 3Withdrawn
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hetrombopag in aplastic anemia, sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 6 months. Planned start Oct 2021; status: withdrawn.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT05018936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018936.